National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
IN THIS ISSUE
Molecular Targets in Cancer Therapy

Drug Discovery at NCI

Animation/VideoAnimation/Video

Audio ClipsAudio Clips

Photos/StillsPhotos/Stills

USEFUL CANCER BACKGROUND
Understanding Cancer Series
Show-and-Tell Tutorials

------

NCI Fact Sheets
Briefs on Cancer Topics

------

NewsCenter
Press Releases

------
SEARCH BENCHMARKS
   
  Between these Dates:      
     
     
Search Benchmarks  
    View All Issues  

MEDIA RESOURCES
Noticias En Español

Understanding Cancer Series

Visuals Online

B-Roll Footage

Radio Broadcasts

Entertainment Resources

Go To Benchmarks Home Page...
Benchmarks
------
VOLUME 2, ISSUE 3
------
Animation/Video

TRANSCRIPT:


Normal Cell

When the epidermal growth factor (EGF) binds to the EGF receptor on the surface of a cell, it initiates a growth signalling pathway. This pathway turns on a gene associated with cell division, which causes the cell to divide into two new cells.

Cancer Cell

Many cancer cells have too many EGF receptors on their surface. Binding of EGF to these receptors results in excessive signalling along growth pathways, leading to unregulated cell division and tumor growth.

Cancer Cell plus Drug

Many cancer drugs currently under development work by targeting the EGF receptor. Some of these drugs target the signalling portion of the receptor inside the cell. Drug binding prevents the receptor from activating the growth pathway. Administering only enough drug to disable some EGF receptors on a cancer cell while leaving a few active will hopefully restore normal signalling and cell division, thus inhibiting tumor growth.


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov